BOOSTERS
-
Cipla in talks to repurpose drugs for Monkeypox, Q1 profit falls 4% to ₹686 cr
Cipla reported net profit of ₹686 crore during for the quarter ended June, down 4% from ₹715 crore for the first quarter of FY22, mainly due to sharp normalisation in Covid portfolio contribution. Its first quarter revenue dropped 2% year on year to ₹5,375 crore from ₹5,504 crore.
-
Uptake of boosters likely to rise in May-June: Official
-
India must use more vaccines in drive, allow boosters to those willing: Experts
-
No booster plan yet for 45-plus with conditions
-
As Omicron threatens a global surge, some countries shorten COVID-19 booster timelines
-
Time for govt to act is now: Virologists on booster dose
-
Oxford researcher urges Britain to donate vaccines rather than give boosters
Advertisement
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
